Isolated lung perfusion for patients with unresectable metastases from sarcoma: a phase I trial

• Published in: The Annals of thoracic surgery Vol. 69; no. 5; pp. 1542 - 1549
• Main Authors: Burt, Michael E, Liu, David, Abolhoda, Amir, Ross, Howard M, Kaneda, Yoshikazu, Jara, Ellen, Casper, Ephraim S, Ginsberg, Robert J, Brennan, Murray F
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier Inc 01.05.2000
• Subjects: Adult; Antineoplastic Agents - administration & dosage; Antineoplastic Agents - pharmacokinetics; Chemotherapy, Cancer, Regional Perfusion; Doxorubicin - administration & dosage; Doxorubicin - pharmacokinetics; Female; Humans; Lung - drug effects; Lung Neoplasms - drug therapy; Lung Neoplasms - secondary; Male; Middle Aged; Sarcoma - drug therapy; Sarcoma - secondary
• ISSN: 0003-4975; 1552-6259
• DOI: 10.1016/S0003-4975(00)01131-0

Background. In patients with unresectable pulmonary metastases from sarcoma, systemic chemotherapy has had limited efficacy possibly because of dose-limiting toxicities. Isolated lung perfusion is an alternative method of delivering high-dose chemotherapy to the lungs while minimizing systemic toxicities. We present the results of our Phase I trial of isolated lung perfusion with doxorubicin hydrochloride in such a group of patients. Methods. From May 1995 to June 1997, 8 patients with unresectable metastases from sarcoma limited to the lungs underwent isolated lung perfusion with doxorubicin. A dose-escalation schedule starting at 40 mg/m2 was used. Seven patients were treated with a dose of 40 mg/m2 or less, and 1 patient received 80 mg/m2. Blood, tumor, and normal lung samples were obtained at various time points during the operation. Patients were evaluated for cardiac, pulmonary, and other toxicities. Results. The doxorubicin concentrations in both normal lung and tumor correlated directly with the amount of doxorubicin in the perfusate. The tumors took up less doxorubicin than the lung. All patients had minimal or undetectable systemic levels of doxorubicin at the conclusion of the perfusion. There were no cardiac or other systemic toxicities. In the 7 patients perfused with 40 mg/m2 or less of doxorubicin, there was a significant decrease in the forced expiratory volume in 1 second and a trend toward a significant decrease in diffusing capacity. The patient who received 80 mg/m2 underwent lung scanning postoperatively, and scans showed no ventilation or perfusion in the perfused lung. There were no perioperative deaths. Two patients are alive with disease, and 6 patients died of disease. The median follow-up is 11 months and the longest, 31 months. There were no partial or complete responses. One patient had stabilization of disease in the perfused lung, whereas the lesions in the untreated lung progressed markedly. Conclusion. Isolated lung perfusion is well tolerated by patients and effectively delivers high doses of doxorubicin to the lung and tumor tissues while minimizing systemic toxicities. A single dose of 80 mg/m2 resulted in substantial injury to the lung. There were no partial or complete responses in patients perfused with doxorubicin at the maximum tolerated dose of 40 mg/m2. Isolated lung perfusion remains a model for testing new and innovative therapies for metastatic sarcoma.